Peptide Therapeutics Market Size, Share & Trends Analysis Report By Application, By Type, By Type of Manufacturers, By Route of Administration, By Synthesis Technology, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Peptide Therapeutics Market Growth & Trends
The global peptide therapeutics market size is expected to reach USD 68.7 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2022 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.
As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.
Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.
The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.
For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.
Peptide Therapeutics Market Report Highlights
Peptide Therapeutics Market Growth & Trends
The global peptide therapeutics market size is expected to reach USD 68.7 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.4% from 2022 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.
As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.
Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.
The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.
For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.
Peptide Therapeutics Market Report Highlights
- By application, cancer held the second-largest revenue share in 2021 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment
- The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class
- By type of manufacturers, the outsourced segment is expected to expand at a lucrative CAGR of 6.6% over the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production
- By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth
- North America held the largest share in terms of revenue in 2021 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives
- Asia Pacific is expected to register a lucrative growth rate of 8.7% over the forecast period. The presence of an established generic industry and API providers in this region, coupled with the growing economic stability in some of the countries, is expected to propel market growth
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Country-wise market: Base estimates
1.2 Global market: CAGR calculation
1.3 Region based segment share calculation
1.4 Research Scope & Assumptions
1.5 List of Data Sources
1.5.1 Data for primary interviews, by sources
1.5.2 Data for primary interviews, by region
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 PEPTIDE THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market segmentation & scope
3.2 Market Driver Analysis
3.2.1 Increasing prevalence of cancer
3.2.2 Rising incidences of metabolic disorder
3.2.3 Presence of strong product pipeline portfolio
3.2.4 Technological Advancement
3.3 Market restraint analysis
3.3.1 Stringent regulations
3.4 Key Opportunities Prioritized
3.4.1 Key opportunities prioritized
3.5 Peptide Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
CHAPTER 4 PEPTIDE THERAPEUTICS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
4.1 Peptide Therapeutics market: Application movement analysis
4.2 Cancer
4.2.1 Cancer market, 2017 - 2030 (USD Million)
4.3 Metabolic
4.3.1 Metabolic market, 2017 - 2030 (USD Million)
4.4 Cardiovascular Disorder
4.4.1 Cardiovascular Disorder market, 2017 - 2030 (USD Million)
4.5 Respiratory
4.5.1 Respiratory market, 2017 - 2030 (USD Million)
4.6 GIT
4.6.1 GIT market, 2017 - 2030 (USD Million)
4.7 Anti-infection
4.7.1 Anti-infection market, 2017 - 2030 (USD Million)
4.8 Pain
4.8.1 Pain market, 2017 - 2030 (USD Million)
4.9 Dermatology
4.9.1 Dermatology market, 2017 - 2030 (USD Million)
4.10 CNS
4.10.1 CNS market, 2017 - 2030 (USD Million)
4.11 Renal
4.11.1 Renal market, 2017 - 2030 (USD Million)
4.12 Others
4.12.1 Others market, 2017 - 2030 (USD Million)
CHAPTER 5 PEPTIDE THERAPEUTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS
5.1 Peptide Therapeutics market: Type movement analysis
5.2 Generic
5.2.1 Generic Market, 2017 - 2030 (USD Million)
5.3 Innovative
5.3.1 Innovative Market, 2017 - 2030 (USD Million)
CHAPTER 6 PEPTIDE THERAPEUTICS MARKET: TYPE OF MANUFACTURERS ESTIMATES & TREND ANALYSIS
6.1 Peptide Therapeutics market: Type of Manufacturers movement analysis
6.2 In-house
6.2.1 In-house market, 2017 - 2030 (USD Million)
6.3 Outsourced
6.3.1 Outsourced market, 2017 - 2030 (USD Million)
CHAPTER 7 PEPTIDE THERAPEUTICS MARKET ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
7.1 Peptide Therapeutics market: Route of Administration movement analysis
7.2 Parenteral
7.2.1 Parenteral market, 2017 - 2030 (USD Million)
7.3 Oral
7.3.1 Oral market, 2017 - 2030 (USD Million)
7.4 Pulmonary
7.4.1 Pulmonary market, 2017 - 2030 (USD Million)
7.5 Mucosal
7.5.1 Mucosal market, 2017 - 2030 (USD Million)
7.6 Others
7.6.1 Others market, 2017 - 2030 (USD Million)
CHAPTER 8 PEPTIDE THERAPEUTICS MARKET SYNTHESIS TECHNOLOGY ESTIMATES & TREND ANALYSIS
8.1 Peptide Therapeutics market: Synthesis Technology movement analysis
8.2 Solid Phase Peptide Synthesis (SPPS)
8.2.1 Solid Phase Peptide Synthesis (SPPS) market, 2017 - 2030 (USD Million)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.3.1 Liquid Phase Peptide Synthesis (LPPS) market, 2017 - 2030 (USD Million)
8.4 Hybrid Technology
8.4.1 Hybrid Technology market, 2017 - 2030 (USD Million)
CHAPTER 9 PEPTIDE THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY SOURCE, PRODUCT, APPLICATION
9.1 Peptide Therapeutics market share by region, 2021 & 2030
9.2 North America
9.2.1 North America Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 U.S. Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.2.3 Canada
9.2.3.1 Canada Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3 Europe
9.3.1 Europe Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3.2 U.K.
9.3.2.1 U.K. Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3.3 Germany
9.3.3.1 Germany Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Japan Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.3 China
9.4.3.1 China Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.4 India
9.4.4.1 India Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5 Latin America
9.5.1 Latin America Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Brazil Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5.3 Mexico
9.5.3.1 Mexico Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.6 MEA
9.6.1 MEA Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.6.2 South Africa
9.6.2.1 South Africa Peptide Therapeutics market, 2017 - 2030 (USD Million)
CHAPTER 10 COMPETITIVE LANDSCAPE
10.1 Strategy Framework
10.2 Market Participation
10.3 Company Profiles
10.3.1 Bachem Holding AG
10.3.1.1 Company overview
10.3.1.2 Financial performance
10.3.1.3 Product benchmarking
10.3.1.4 Strategic initiatives
10.3.2 Eli Lilly and Company
10.3.2.1 Company overview
10.3.2.2 Financial performance
10.3.2.3 Product benchmarking
10.3.2.4 Strategic initiatives
10.3.3 Pfizer Inc.
10.3.3.1 Company overview
10.3.3.2 Financial performance
10.3.3.3 Product benchmarking
10.3.3.4 Strategic initiatives
10.3.4 Amgen Inc.
10.3.4.1 Company overview
10.3.4.2 Financial performance
10.3.4.3 Product benchmarking
10.3.4.4 Strategic initiatives
10.3.5 Takeda Pharmaceutical Company Limited
10.3.5.1 Company overview
10.3.5.2 Financial performance
10.3.5.3 Product benchmarking
10.3.5.4 Strategic initiatives
10.3.6 Teva Pharmaceutical
10.3.6.1 Company overview
10.3.6.2 Financial performance
10.3.6.3 Product benchmarking
10.3.6.4 Strategic initiatives
10.3.7 Lonza Inc.
10.3.7.1 Company overview
10.3.7.2 Financial performance
10.3.7.3 Product benchmarking
10.3.7.4 Strategic initiatives
10.3.8 Sanofi
10.3.8.1 Company overview
10.3.8.2 Financial performance
10.3.8.3 Product benchmarking
10.3.8.4 Strategic initiatives
10.3.9 Bristol-Myers Squibb(BMS)
10.3.9.1 Company overview
10.3.9.2 Financial performance
10.3.9.3 Product benchmarking
10.3.9.4 Strategic initiatives
10.3.10 AstraZeneca PLC
10.3.10.1 Company overview
10.3.10.2 Financial performance
10.3.10.3 Product benchmarking
10.3.10.4 Strategic initiatives
10.3.11 GlaxoSmithKline (GSK)
10.3.11.1 Company overview
10.3.11.2 Financial performance
10.3.11.3 Product benchmarking
10.3.11.4 Strategic initiatives
10.3.12 Novartis AG
10.3.12.1 Company overview
10.3.12.2 Financial performance
10.3.12.3 Product benchmarking
10.3.12.4 Strategic initiatives
10.3.13 Novo Nordisk A/S
10.3.13.1 Company overview
10.3.13.2 Financial performance
10.3.13.3 Product benchmarking
10.3.13.4 Strategic initiatives
1.1 Country-wise market: Base estimates
1.2 Global market: CAGR calculation
1.3 Region based segment share calculation
1.4 Research Scope & Assumptions
1.5 List of Data Sources
1.5.1 Data for primary interviews, by sources
1.5.2 Data for primary interviews, by region
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 PEPTIDE THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market segmentation & scope
3.2 Market Driver Analysis
3.2.1 Increasing prevalence of cancer
3.2.2 Rising incidences of metabolic disorder
3.2.3 Presence of strong product pipeline portfolio
3.2.4 Technological Advancement
3.3 Market restraint analysis
3.3.1 Stringent regulations
3.4 Key Opportunities Prioritized
3.4.1 Key opportunities prioritized
3.5 Peptide Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
CHAPTER 4 PEPTIDE THERAPEUTICS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
4.1 Peptide Therapeutics market: Application movement analysis
4.2 Cancer
4.2.1 Cancer market, 2017 - 2030 (USD Million)
4.3 Metabolic
4.3.1 Metabolic market, 2017 - 2030 (USD Million)
4.4 Cardiovascular Disorder
4.4.1 Cardiovascular Disorder market, 2017 - 2030 (USD Million)
4.5 Respiratory
4.5.1 Respiratory market, 2017 - 2030 (USD Million)
4.6 GIT
4.6.1 GIT market, 2017 - 2030 (USD Million)
4.7 Anti-infection
4.7.1 Anti-infection market, 2017 - 2030 (USD Million)
4.8 Pain
4.8.1 Pain market, 2017 - 2030 (USD Million)
4.9 Dermatology
4.9.1 Dermatology market, 2017 - 2030 (USD Million)
4.10 CNS
4.10.1 CNS market, 2017 - 2030 (USD Million)
4.11 Renal
4.11.1 Renal market, 2017 - 2030 (USD Million)
4.12 Others
4.12.1 Others market, 2017 - 2030 (USD Million)
CHAPTER 5 PEPTIDE THERAPEUTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS
5.1 Peptide Therapeutics market: Type movement analysis
5.2 Generic
5.2.1 Generic Market, 2017 - 2030 (USD Million)
5.3 Innovative
5.3.1 Innovative Market, 2017 - 2030 (USD Million)
CHAPTER 6 PEPTIDE THERAPEUTICS MARKET: TYPE OF MANUFACTURERS ESTIMATES & TREND ANALYSIS
6.1 Peptide Therapeutics market: Type of Manufacturers movement analysis
6.2 In-house
6.2.1 In-house market, 2017 - 2030 (USD Million)
6.3 Outsourced
6.3.1 Outsourced market, 2017 - 2030 (USD Million)
CHAPTER 7 PEPTIDE THERAPEUTICS MARKET ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
7.1 Peptide Therapeutics market: Route of Administration movement analysis
7.2 Parenteral
7.2.1 Parenteral market, 2017 - 2030 (USD Million)
7.3 Oral
7.3.1 Oral market, 2017 - 2030 (USD Million)
7.4 Pulmonary
7.4.1 Pulmonary market, 2017 - 2030 (USD Million)
7.5 Mucosal
7.5.1 Mucosal market, 2017 - 2030 (USD Million)
7.6 Others
7.6.1 Others market, 2017 - 2030 (USD Million)
CHAPTER 8 PEPTIDE THERAPEUTICS MARKET SYNTHESIS TECHNOLOGY ESTIMATES & TREND ANALYSIS
8.1 Peptide Therapeutics market: Synthesis Technology movement analysis
8.2 Solid Phase Peptide Synthesis (SPPS)
8.2.1 Solid Phase Peptide Synthesis (SPPS) market, 2017 - 2030 (USD Million)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.3.1 Liquid Phase Peptide Synthesis (LPPS) market, 2017 - 2030 (USD Million)
8.4 Hybrid Technology
8.4.1 Hybrid Technology market, 2017 - 2030 (USD Million)
CHAPTER 9 PEPTIDE THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY SOURCE, PRODUCT, APPLICATION
9.1 Peptide Therapeutics market share by region, 2021 & 2030
9.2 North America
9.2.1 North America Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.2.2 U.S.
9.2.2.1 U.S. Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.2.3 Canada
9.2.3.1 Canada Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3 Europe
9.3.1 Europe Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3.2 U.K.
9.3.2.1 U.K. Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.3.3 Germany
9.3.3.1 Germany Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.2 Japan
9.4.2.1 Japan Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.3 China
9.4.3.1 China Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.4.4 India
9.4.4.1 India Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5 Latin America
9.5.1 Latin America Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5.2 Brazil
9.5.2.1 Brazil Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.5.3 Mexico
9.5.3.1 Mexico Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.6 MEA
9.6.1 MEA Peptide Therapeutics market, 2017 - 2030 (USD Million)
9.6.2 South Africa
9.6.2.1 South Africa Peptide Therapeutics market, 2017 - 2030 (USD Million)
CHAPTER 10 COMPETITIVE LANDSCAPE
10.1 Strategy Framework
10.2 Market Participation
10.3 Company Profiles
10.3.1 Bachem Holding AG
10.3.1.1 Company overview
10.3.1.2 Financial performance
10.3.1.3 Product benchmarking
10.3.1.4 Strategic initiatives
10.3.2 Eli Lilly and Company
10.3.2.1 Company overview
10.3.2.2 Financial performance
10.3.2.3 Product benchmarking
10.3.2.4 Strategic initiatives
10.3.3 Pfizer Inc.
10.3.3.1 Company overview
10.3.3.2 Financial performance
10.3.3.3 Product benchmarking
10.3.3.4 Strategic initiatives
10.3.4 Amgen Inc.
10.3.4.1 Company overview
10.3.4.2 Financial performance
10.3.4.3 Product benchmarking
10.3.4.4 Strategic initiatives
10.3.5 Takeda Pharmaceutical Company Limited
10.3.5.1 Company overview
10.3.5.2 Financial performance
10.3.5.3 Product benchmarking
10.3.5.4 Strategic initiatives
10.3.6 Teva Pharmaceutical
10.3.6.1 Company overview
10.3.6.2 Financial performance
10.3.6.3 Product benchmarking
10.3.6.4 Strategic initiatives
10.3.7 Lonza Inc.
10.3.7.1 Company overview
10.3.7.2 Financial performance
10.3.7.3 Product benchmarking
10.3.7.4 Strategic initiatives
10.3.8 Sanofi
10.3.8.1 Company overview
10.3.8.2 Financial performance
10.3.8.3 Product benchmarking
10.3.8.4 Strategic initiatives
10.3.9 Bristol-Myers Squibb(BMS)
10.3.9.1 Company overview
10.3.9.2 Financial performance
10.3.9.3 Product benchmarking
10.3.9.4 Strategic initiatives
10.3.10 AstraZeneca PLC
10.3.10.1 Company overview
10.3.10.2 Financial performance
10.3.10.3 Product benchmarking
10.3.10.4 Strategic initiatives
10.3.11 GlaxoSmithKline (GSK)
10.3.11.1 Company overview
10.3.11.2 Financial performance
10.3.11.3 Product benchmarking
10.3.11.4 Strategic initiatives
10.3.12 Novartis AG
10.3.12.1 Company overview
10.3.12.2 Financial performance
10.3.12.3 Product benchmarking
10.3.12.4 Strategic initiatives
10.3.13 Novo Nordisk A/S
10.3.13.1 Company overview
10.3.13.2 Financial performance
10.3.13.3 Product benchmarking
10.3.13.4 Strategic initiatives
LIST OF TABLES
TABLE 1 Factors used in segment share estimation
TABLE 2 List of secondary data sources
TABLE 3 Primary interview details, by source
TABLE 4 Primary interview details, by region
TABLE 5 North America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 6 North America Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 7 North America Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 8 North America Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 9 North America Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 10 U.S. Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 11 U.S. Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 12 U.S. Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 13 U.S. Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 14 U.S. Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 15 Canada Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 16 Canada Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 17 Canada Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 18 Canada Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 19 Canada Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 20 Europe Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 21 Europe Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 22 Europe Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 23 Europe Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 24 Europe Peptide Therapeutics Market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 25 U.K. Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 26 U.K. Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 27 U.K. Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 28 U.K. Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 29 U.K. Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 30 Germany Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 31 Germany Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 32 Germany Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 33 Germany Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 34 Germany Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 35 Asia Pacific Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 36 Asia Pacific Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 37 Asia Pacific Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 38 Asia Pacific Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 39 Asia Pacific Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 40 Japan Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 41 Japan Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 42 Japan Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 43 Japan Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 44 Japan Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 45 China Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 46 China Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 47 China Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 48 China Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 49 China Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 50 India Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 51 India Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 52 India Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 53 India Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 54 India Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 55 Latin America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 56 Latin America Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 57 Latin America Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 58 Latin America Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 59 Latin America Peptide Therapeutics Market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 60 Brazil America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 61 Brazil Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 62 Brazil Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 63 Brazil Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 64 Brazil Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 65 Mexico America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 66 Mexico Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 67 Mexico Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 68 Mexico Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 69 Mexico Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 70 MEA America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 71 MEA Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 72 MEA Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 73 MEA Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 74 MEA Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 75 South Africa Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 76 South Africa Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 77 South Africa Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 78 South Africa Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 79 South Africa Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 1 Factors used in segment share estimation
TABLE 2 List of secondary data sources
TABLE 3 Primary interview details, by source
TABLE 4 Primary interview details, by region
TABLE 5 North America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 6 North America Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 7 North America Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 8 North America Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 9 North America Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 10 U.S. Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 11 U.S. Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 12 U.S. Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 13 U.S. Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 14 U.S. Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 15 Canada Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 16 Canada Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 17 Canada Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 18 Canada Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 19 Canada Peptide Therapeutics market, synthesis technology, 2017 - 2030 (USD Million)
TABLE 20 Europe Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 21 Europe Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 22 Europe Peptide Therapeutics market, by type of manufacturers, 2017 - 2030 (USD Million)
TABLE 23 Europe Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 24 Europe Peptide Therapeutics Market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 25 U.K. Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 26 U.K. Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 27 U.K. Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 28 U.K. Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 29 U.K. Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 30 Germany Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 31 Germany Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 32 Germany Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 33 Germany Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 34 Germany Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 35 Asia Pacific Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 36 Asia Pacific Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 37 Asia Pacific Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 38 Asia Pacific Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 39 Asia Pacific Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 40 Japan Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 41 Japan Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 42 Japan Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 43 Japan Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 44 Japan Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 45 China Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 46 China Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 47 China Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 48 China Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 49 China Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 50 India Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 51 India Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 52 India Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 53 India Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 54 India Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 55 Latin America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 56 Latin America Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 57 Latin America Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 58 Latin America Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 59 Latin America Peptide Therapeutics Market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 60 Brazil America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 61 Brazil Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 62 Brazil Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 63 Brazil Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 64 Brazil Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 65 Mexico America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 66 Mexico Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 67 Mexico Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 68 Mexico Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 69 Mexico Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 70 MEA America Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 71 MEA Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 72 MEA Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 73 MEA Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 74 MEA Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
TABLE 75 South Africa Peptide Therapeutics market, by application, 2017 - 2030 (USD Million)
TABLE 76 South Africa Peptide Therapeutics market, by type, 2017 - 2030 (USD Million)
TABLE 77 South Africa Peptide Therapeutics market, by type of administration, 2017 - 2030 (USD Million)
TABLE 78 South Africa Peptide Therapeutics market, by route of administration, 2017 - 2030 (USD Million)
TABLE 79 South Africa Peptide Therapeutics market, by synthesis technology, 2017 - 2030 (USD Million)
LIST OF FIGURES
FIG. 1 Primary interviews, by sources
FIG. 2 Market summary
FIG. 3 Market trends & outlook
FIG. 4 Market segmentation & scope
FIG. 5 Market driver relevance analysis (Current & future impact)
FIG. 6 Market restraint relevance analysis (Current & future impact)
FIG. 7 Key opportunities prioritized
FIG. 8 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 9 Porter’s Five Forces Analysis
FIG. 10 Peptide Therapeutics market, Application outlook: Key takeaways
FIG. 11 Peptide Therapeutics market: Application movement analysis
FIG. 12 Cancer market, 2017 - 2030 (USD Million)
FIG. 13 Metabolic market, 2017 - 2030 (USD Million)
FIG. 14 Cardiovascular Disorder market, 2017 - 2030 (USD Million)
FIG. 15 Respiratory market, 2017 - 2030 (USD Million)
FIG. 16 GIT market, 2017 - 2030 (USD Million)
FIG. 17 Anti-infection market, 2017 - 2030 (USD Million)
FIG. 18 Pain market, 2017 - 2030 (USD Million)
FIG. 19 Dermatology market, 2017 - 2030 (USD Million)
FIG. 20 CNS market, 2017 - 2030 (USD Million)
FIG. 21 Renal market, 2017 - 2030 (USD Million)
FIG. 22 Others market, 2017 - 2030 (USD Million)
FIG. 23 Peptide Therapeutics market, type outlook: Key takeaways
FIG. 24 Peptide Therapeutics Market: Type movement analysis
FIG. 25 Generic market, 2017 - 2030 (USD Million)
FIG. 26 Innovative market, 2017 - 2030 (USD Million)
FIG. 27 Peptide Therapeutics market, Type of Manufacturers outlook: Key takeaways
FIG. 28 Peptide Therapeutics Market: Type of Manufacturers movement analysis
FIG. 29 In-house market, 2017 - 2030 (USD Million)
FIG. 30 Outsourced market, 2017 - 2030 (USD Million)
FIG. 31 Peptide Therapeutics market, Route of Administration outlook: Key takeaways
FIG. 32 Peptide Therapeutics Market: Route of Administration movement analysis
FIG. 33 Parental market, 2017 - 2030 (USD Million)
FIG. 34 Oral market, 2017 - 2030 (USD Million)
FIG. 35 Pulmonary market, 2017 - 2030 (USD Million)
FIG. 36 Mucosal market, 2017 - 2030 (USD Million)
FIG. 37 Others market, 2017 - 2030 (USD Million)
FIG. 38 Peptide Therapeutics market, Synthesis Technology outlook: Key takeaways
FIG. 39 Peptide Therapeutics Market: Synthesis Technology movement analysis
FIG. 40 Solid Phase Peptide Synthesis (SPPS) market, 2017 - 2030 (USD Million)
FIG. 41 Liquid Phase Peptide Synthesis (LPPS) market, 2017 - 2030 (USD Million)
FIG. 42 Hybrid Technology market, 2017 - 2030 (USD Million)
FIG. 43 Regional market place: Key takeaways
FIG. 44 Regional outlook, 2021 & 2030
FIG. 45 Strategy framework
FIG. 46 Market participation and categorization
FIG. 1 Primary interviews, by sources
FIG. 2 Market summary
FIG. 3 Market trends & outlook
FIG. 4 Market segmentation & scope
FIG. 5 Market driver relevance analysis (Current & future impact)
FIG. 6 Market restraint relevance analysis (Current & future impact)
FIG. 7 Key opportunities prioritized
FIG. 8 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 9 Porter’s Five Forces Analysis
FIG. 10 Peptide Therapeutics market, Application outlook: Key takeaways
FIG. 11 Peptide Therapeutics market: Application movement analysis
FIG. 12 Cancer market, 2017 - 2030 (USD Million)
FIG. 13 Metabolic market, 2017 - 2030 (USD Million)
FIG. 14 Cardiovascular Disorder market, 2017 - 2030 (USD Million)
FIG. 15 Respiratory market, 2017 - 2030 (USD Million)
FIG. 16 GIT market, 2017 - 2030 (USD Million)
FIG. 17 Anti-infection market, 2017 - 2030 (USD Million)
FIG. 18 Pain market, 2017 - 2030 (USD Million)
FIG. 19 Dermatology market, 2017 - 2030 (USD Million)
FIG. 20 CNS market, 2017 - 2030 (USD Million)
FIG. 21 Renal market, 2017 - 2030 (USD Million)
FIG. 22 Others market, 2017 - 2030 (USD Million)
FIG. 23 Peptide Therapeutics market, type outlook: Key takeaways
FIG. 24 Peptide Therapeutics Market: Type movement analysis
FIG. 25 Generic market, 2017 - 2030 (USD Million)
FIG. 26 Innovative market, 2017 - 2030 (USD Million)
FIG. 27 Peptide Therapeutics market, Type of Manufacturers outlook: Key takeaways
FIG. 28 Peptide Therapeutics Market: Type of Manufacturers movement analysis
FIG. 29 In-house market, 2017 - 2030 (USD Million)
FIG. 30 Outsourced market, 2017 - 2030 (USD Million)
FIG. 31 Peptide Therapeutics market, Route of Administration outlook: Key takeaways
FIG. 32 Peptide Therapeutics Market: Route of Administration movement analysis
FIG. 33 Parental market, 2017 - 2030 (USD Million)
FIG. 34 Oral market, 2017 - 2030 (USD Million)
FIG. 35 Pulmonary market, 2017 - 2030 (USD Million)
FIG. 36 Mucosal market, 2017 - 2030 (USD Million)
FIG. 37 Others market, 2017 - 2030 (USD Million)
FIG. 38 Peptide Therapeutics market, Synthesis Technology outlook: Key takeaways
FIG. 39 Peptide Therapeutics Market: Synthesis Technology movement analysis
FIG. 40 Solid Phase Peptide Synthesis (SPPS) market, 2017 - 2030 (USD Million)
FIG. 41 Liquid Phase Peptide Synthesis (LPPS) market, 2017 - 2030 (USD Million)
FIG. 42 Hybrid Technology market, 2017 - 2030 (USD Million)
FIG. 43 Regional market place: Key takeaways
FIG. 44 Regional outlook, 2021 & 2030
FIG. 45 Strategy framework
FIG. 46 Market participation and categorization
